A clinical trial to learn more about the effects of votoplam (HTT227) in people with Huntington’s disease

You likely can't join if

• • History of gene therapy or cell transplantation or any other experimental brain surgery for the treatment of HD
• • Serologic evidence for active viral hepatitis as indicated by: • positive anti-HBc IgM • positive anti-HBc IgG confirmed by positive HBsAg and/or HBV DNA • positive HCV ab test confirmed by positive HCV RNA • Immunodeficiency diseases, including a positive human immunodeficiency virus (HIV) test result
• Women of childbearing potential, defined as all women physiologically capable of becoming pregnant from menarche until becoming post-menopausal, unless they have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or bilateral salpingectomy at least six weeks before taking study treatment. In the case of oophorectomy alone, the reproductive status of the woman needs to have been confirmed by follow-up hormone level assessment. WOCBP are excluded unless they are using highly effective methods of contraception (failure rate < 1% per year) while taking study treatment and for 8 months after stopping study treatment.
• Pregnant or nursing (breastfeeding) women
• • History or current diagnosis of ECG or cardiac abnormalities indicating significant risk of safety for participants such as: • Concomitant clinically significant cardiac arrhythmias, e.g., sustained ventricular tachycardia, and clinically significant second- or third-degree AV block without a pacemaker • History of familial long QT syndrome or known family history of Torsade de Pointes